article thumbnail

Review Paper: Clinical Evidence Lacking in Support of CBD as an Anti-Viral Agent

NORML

There is an absence of clinical data supporting the efficacy of CBD as an antiviral agent, according to a systematic literature review published in the journal Cannabis and Cannabinoid Research. Yet, despite this lack of clinical data, authors identified numerous commercial websites touting CBD as a clinically beneficial antiviral agent.

CBD 311
article thumbnail

Maine: Governor Signs Legislation Finalizing Rules for Retail Marijuana Sales

NORML

Janet Mills on Thursday signed legislation finalizing regulations governing the licensed production and retail sale of cannabis to adults. With the passage of the new rules, it is estimated that marijuana retailers may be operational by March 2020. Retailers will not be permitted to sell customers more than 2.5 Democratic Gov.

Retail 204
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Georgia: Regulators Finally License Retailers to Begin Selling Low-THC Cannabis Products to Authorized Patients

NORML

"For almost ten years, patients and their providers have lacked the ability to locally access these medically necessary state-approved products from state-licensed retailers. The post Georgia: Regulators Finally License Retailers to Begin Selling Low-THC Cannabis Products to Authorized Patients appeared first on NORML.

Retail 219
article thumbnail

FDA Sends Warning Letters to Multiple Companies for Illegally Marketing CBD Products

NORML

Representatives of the US Food and Drug Administration issued warning letters on Monday to multiple companies for marketing CBD-specific products in ways that violate federal law. Currently, commercially available CBD products are not regulated by the FDA, despite the fact that some three in four Americans presume otherwise.

CBD 245
article thumbnail

NORML Submits Comments to FDA Ahead of CBD Hearing

NORML

NORML has submitted written comments to the US Food and Drug Administration ahead of the agency’s scheduled hearing on the regulation CBD-infused products. Currently, commercially marketed CBD-infused products are not subject to explicit federal regulations.

CBD 235
article thumbnail

FDA Hearing On ‘Hemp-Derived CBD’ Today

NORML

Washington, DC : Today the US Food and Drug Administration is taking in-person public testimony with regard to the “manufacturing, product quality, marketing, labeling, and sale” of CBD-infused retail products. ” Currently, commercially marketed CBD-infused products are not subject to explicit federal regulations.

Hemp 225
article thumbnail

A NORML Reminder: Beware of COVID-19 Cure All Claims

NORML

The National Organization for the Reform of Marijuana Laws wishes to reiterate its message that cannabis consumers and others beware of online misinformation surrounding the use of either whole-plant cannabis or CBD as a potential remedy for the COVID-19 virus. Some of these marketers are explicitly targeting cannabis consumers.

CBD 352